FY2029 Earnings Estimate for MNPR Issued By HC Wainwright

Monopar Therapeutics Inc. (NASDAQ:MNPR) – Equities researchers at HC Wainwright issued their FY2029 earnings estimates for shares of Monopar Therapeutics in a research note issued on Wednesday, January 22nd. HC Wainwright analyst S. Lee anticipates that the company will earn $3.66 per share for the year. HC Wainwright has a “Buy” rating and a $40.00 price objective on the stock. The consensus estimate for Monopar Therapeutics’ current full-year earnings is ($1.65) per share.

Other equities research analysts have also issued research reports about the company. Rodman & Renshaw started coverage on Monopar Therapeutics in a research report on Friday, October 11th. They issued a “buy” rating and a $50.00 target price on the stock. Piper Sandler started coverage on shares of Monopar Therapeutics in a report on Friday, January 10th. They set an “overweight” rating and a $72.00 price target on the stock.

Monopar Therapeutics Stock Performance

MNPR stock traded up $0.08 during midday trading on Thursday, reaching $33.75. The stock had a trading volume of 8,137 shares, compared to its average volume of 47,243. The firm has a fifty day simple moving average of $23.76 and a two-hundred day simple moving average of $12.15. The stock has a market cap of $205.84 million, a PE ratio of -17.13 and a beta of 1.23. Monopar Therapeutics has a 52-week low of $1.54 and a 52-week high of $38.50.

Monopar Therapeutics (NASDAQ:MNPR) last released its quarterly earnings data on Friday, November 8th. The company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($0.46) by $0.09.

Insider Activity at Monopar Therapeutics

In related news, CFO Karthik Radhakrishnan bought 1,550 shares of the firm’s stock in a transaction that occurred on Monday, October 28th. The shares were acquired at an average cost of $16.25 per share, with a total value of $25,187.50. Following the completion of the transaction, the chief financial officer now owns 1,550 shares of the company’s stock, valued at approximately $25,187.50. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 34.90% of the stock is currently owned by corporate insiders.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.